News

The Most Notable New Airline Routes This Week
Welcome to my 170th weekly routes article! It includes 10 mini-stories about subjectively exciting services that took off ...
ascopubs.org6d
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Precision Palliative Care as a Pragmatic Solution for a Care Delivery Problem This study evaluated tarlatamab in patients with relapsed/refractory SCLC. The primary end point was safety. Secondary end ...